Clinical evaluation of Asparagine Synthetase (ASNS) Level in Leukemia/ Lymphoma Cells by Monoclonal Antibodies

Not Applicable

• Conditions: eukemia/Lymphoma

• Registration Number: JPRN-UMIN000012119
• Lead Sponsor: Aichi Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-11-01
• Study Completion: 2017-03-31
• Results First Posted: 2019-10-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with concomitant active cancer 2) Patients with active viral hepatitis or HBs-Ag positive 3) Patients with known CNS involvement of the lymphoma 4) Patients with previous serious allergy to any of the drugs given 5) Patients with abnormalities in cardiac function or clinically significant heart disease such as acute myocardial infarction or unstable angina within 6 months prior to the start of study treatment, heart failure NYHA class III or IV, uncontrolled hypertension or poor compliance of antihypertensive treatment, uncontrolled arrhythmias 6) Patients with serious or uncontrolled medical condition such as uncontrolled diabetes, uncontrolled active infection, significant cerebrovascular disease or poorly controlled psychiatric disease 7) Patients unable to give written informed consent 8) Others: Inappropriate patients determined by a principal investigator or sub-investigators

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of the effectiveness of flow cytometric estimation of ASNS Level in Leukemia/ Lymphoma or Suspension Cells by this Monoclonal Antibody.

Secondary Outcome Measures

Name	Time	Method
To make sure that leukemia cells with low ASNS expression are sensitive to L-asparaginase in vitro MTT/WST-1 assay.